--- title: "CSBIO released its performance for the first three quarters, with a net loss attributable to shareholders of 44.8174 million yuan" type: "News" locale: "en" url: "https://longbridge.com/en/news/263306639.md" description: "According to the Zhitong Finance APP, CSBIO released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 681 million yuan, a year-on-year decrease of 13.11%. The net loss attributable to shareholders of the listed company was 44.8174 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 47.687 million yuan. The basic loss per share was 0.05 yuan" datetime: "2025-10-29T13:37:08.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/263306639.md) - [en](https://longbridge.com/en/news/263306639.md) - [zh-HK](https://longbridge.com/zh-HK/news/263306639.md) --- # CSBIO released its performance for the first three quarters, with a net loss attributable to shareholders of 44.8174 million yuan According to the Zhitong Finance APP, CSBIO (300255.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 681 million yuan, a year-on-year decrease of 13.11%. The net loss attributable to shareholders of the listed company was 44.8174 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 47.687 million yuan. The basic loss per share was 0.05 yuan ### Related Stocks - [300255.CN](https://longbridge.com/en/quote/300255.CN.md) ## Related News & Research - [12:15 ETInventHelp Inventors Develop New Track System for Refrigerator Shelves (TKI-1242)](https://longbridge.com/en/news/286943935.md) - [TerraPower signs Natrium supply framework agreement with HD Hyundai Heavy Industries](https://longbridge.com/en/news/287065044.md) - [MyEco Group Lands Penrith Council FOGO Liner Contract](https://longbridge.com/en/news/286989054.md) - [First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial](https://longbridge.com/en/news/286888745.md) - [](https://longbridge.com/en/news/286948461.md)